ReviewCurrent hypertension reports2023
Key to the Treatment of Primary Aldosteronism in Secondary Hypertension: Subtype Diagnosis.
Review in Current hypertension reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Prevalence and risk of thyroid disease among adult primary aldosteronism patients: a systematic review, meta-analysis, and trial sequential analysis.Frontiers in endocrinology · 2025Pooled it
- Efficacy, Quality of Life, and Cost-Effectiveness of Superselective Adrenal Arterial Embolization in Idiopathic Hyperaldosteronism: A Comparative Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Establishment and evaluation of a patient-derived organoids-based xenograft model of primary aldosteronism using [Journal of translational medicine · 2025Article
- ccfDNA analysis for the classification of adrenocortical adenomas.Journal of endocrinological investigation · 2025Article
- Artificial intelligence in primary aldosteronism: current achievements and future challenges.Frontiers in molecular biosciences · 2025Review
- The value of targeted CXCR4Frontiers in endocrinology · 2025Article
- Development and validation of prediction models for special subtype of primary aldosteronism: patients with negative adrenal CT imaging.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewPrimary aldosteronism (PA) is a leading global cause of secondary hypertension. Subtyping diagnosis of PA is the key to surgery, but accurate classification of PA is crucial but challenging in clinical diagnosis and treatment. The purpose of this review is to provide a summary of current literature and propose subtyping diagnosis flow chart to help us classify PA quickly and accurately. RECENT
findingsEarly diagnosis and accurate typing are essential for the timely treatment and appropriate management of PA. For most patients, adrenal venous sampling (AVS) is the central choice for typing diagnosis, but AVS is invasive and difficult to promote effectively. CT can help identify unilateral typical adenomas in select patients to avoid AVS. New radionuclide imaging has shown value in the diagnosis and classification of PA, which distinguishes adrenocortical hyperplasia from adenoma and can replace AVS in some patients. Accurately diagnosing unilateral PA is crucial for determining the appropriate treatment strategy for PA. The simple flow chart of PA subtyping diagnosis based on the current literature needs to be verified and evaluated by follow-up researches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.